On August 9, 2024, following a portfolio review, the Company’s Board of Directors approved a restructuring plan (“Restructuring Plan”) designed to re-prioritize the Company’s resources to focus on its core MCED business and reduce overall spend as the Company progresses towards completion of registrational studies and premarket approval application submission. The Restructuring Plan was substantially completed in the fourth quarter of 2024, and the Company incurred approximately $18.3 million of total restructuring charges from August 9, 2024 through December 31, 2024, consisting primarily of employee severance, benefits, payroll taxes, asset impairments and other associated costs. The following table presents the total restructuring charges by function for the periods indicated:


	Year Ended December 31, 2025
(in thousands)	Severance and related benefit costs		Other Costs		Total
Research and development	$	(47)	$	111	$	64
Sales and marketing	(83)		—		(83)
General and administrative	(31)		16		(15)
Total	$	(161)	$	127	$	(34)


	Year Ended December 31, 2024
(in thousands)	Severance and related benefit costs		Other Costs		Total
Research and development	$	8,783	$	297	$	9,080
Sales and marketing	4,858		—		4,858
General and administrative	3,897		478		4,375
Total	$	17,538	$	775	$	18,313


(in thousands)	Severance and related benefit costs		Other Costs		Total
Restructuring charges	$	17,538	$	775	$	18,313
Cash payments made	(16,732)		(454)		(17,186)
Non-cash charges	—		(99)		(99)
Amount recorded in accrued liabilities as of December 31, 2024	806		222		1,028
Restructuring charges	(161)		127		(34)
Cash payments made	(645)		(349)		(994)
Amount recorded in accrued liabilities as of December 31, 2025	$	—	$	—	$	—